Category Archives: Global News Feed

Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.

See original here:
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Continue reading here:
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

Go here to read the rest:
Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn

Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

View original post here:
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx

GHENT, Belgium, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in the following upcoming virtual investor conferences.

Here is the original post:
Sequana Medical announces February-March 2021 Investor Conference Schedule

NANTES, France, Feb. 15, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has signed a loan agreement of up to €25 million with the European Investment Bank (EIB).

Excerpt from:
OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank